Gwenn M. Hansen, Ph.D., has served as Chief Scientific Officer of Nurix since June 2020, serving as the company’s Senior Vice President of Research prior to that. Since joining Nurix in 2015, Dr. Hansen established the company’s small molecule discovery platform which utilizes DNA encoded library technology and high throughput chemistry and has leveraged its scalability to deliver multiple clinical candidates for both Nurix’s internal pipeline as well as its partnered pipelines. Prior to joining Nurix, Dr. Hansen was an Associate Professor in the Center for Drug Discovery at Baylor College of Medicine and Senior Director of Discovery Technologies at Lexicon Pharmaceuticals. Dr. Hansen earned her Ph.D. in Biomedical Sciences from the University of Tennessee-Knoxville and completed post-doctoral training at M.D. Anderson Cancer Center.